Skip to Content
NIH - National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Center for Cancer Research
NCI Experimental Therapeutics Program (NExT)
Contact NExT
Show menu
Search this site

News

Chemical Biology Consortium

The Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) Program brought together chemical biologists and molecular oncologists from government, industry, and academia to address unmet therapeutic needs in oncology. The CBC operates as a collaborative network of 7 Dedicated and 15 Specialized Centers across the U.S. that support the advancement of NExT discovery projects, provide scientific leadership, and provide technologies to projects. The CBC Fall Symposium, sponsored by NCI, convened on November 16, 2018 at the University of California, San Francisco’s Mission Bay Campus in San Francisco, CA. Members of the CBC and the Bay Area scientific community met to discuss emerging concepts, novel technologies, and therapeutic strategies in drug discovery and development, with a particular emphasis on bridging the gaps between discoveries in academic settings and translation or advancement of those hypotheses into novel therapeutics.


Partnership to Develop Novel Treatment Approaches

On March 18th, Boehringer Ingelheim and Vanderbilt University announced a collaboration to fight cancer through the licensing of a drug discovery program that matured in the NCI Experimental Therapeutics (NExT) program. The Fesik laboratory at Vanderbilt University in collaboration with the Chemical Biology Consortium made impressive strides in developing inhibitors of Mcl-1. The partnership with Boehringer Ingelheim will facilitate the advancement of these promising therapeutics towards clinical development with the potential of delivering a new cancer drug to market.

Who is the NExT Program for?

Domestic and international researchers in academia, nonprofit, government & industry

What does the NExT Program do?

NExT is NOT a grant mechanism. Instead, NExT provides resources for projects focused on developing therapies for unmet needs that are not adequately addressed by the private sector.

News

Chemical Biology Consortium

The Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) Program brought together chemical biologists and molecular oncologists from government, industry, and academia to address unmet therapeutic needs in oncology. The CBC operates as a collaborative network of 7 Dedicated and 15 Specialized Centers across the U.S. that support the advancement of NExT discovery projects, provide scientific leadership, and provide technologies to projects. The CBC Fall Symposium, sponsored by NCI, convened on November 16, 2018 at the University of California, San Francisco’s Mission Bay Campus in San Francisco, CA. Members of the CBC and the Bay Area scientific community met to discuss emerging concepts, novel technologies, and therapeutic strategies in drug discovery and development, with a particular emphasis on bridging the gaps between discoveries in academic settings and translation or advancement of those hypotheses into novel therapeutics.


Partnership to Develop Novel Treatment Approaches

On March 18th, Boehringer Ingelheim and Vanderbilt University announced a collaboration to fight cancer through the licensing of a drug discovery program that matured in the NCI Experimental Therapeutics (NExT) program. The Fesik laboratory at Vanderbilt University in collaboration with the Chemical Biology Consortium made impressive strides in developing inhibitors of Mcl-1. The partnership with Boehringer Ingelheim will facilitate the advancement of these promising therapeutics towards clinical development with the potential of delivering a new cancer drug to market.